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SEVERE SEPSIS, A SYNDROME OFacute infection complicated byorgan dysfunction, is caused bya dysregulated systemic inflam-
matory response. Sepsis can progress to
systemic hypotension (septic shock),
Importance Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide
(LPS) from binding at the cell surface MD2-TLR4 receptor. LPS is a major component
of the outer membrane of gram-negative bacteria and is a potent activator of the acute
inflammatory response.
Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce
sepsis-induced mortality.
Design, Setting, and Participants We performed a randomized, double-blind,
placebo-controlled, multinational phase 3 trial in 197 intensive care units. Patients were
enrolled from June 2006 to September 2010 and final follow-up was completed in
September 2011.
Interventions Patients with severe sepsis (n=1961) were randomized and treated
within 12 hours of onset of first organ dysfunction in a 2:1 ratio with a 6-day course
of either eritoran tetrasodium (105 mg total) or placebo, with n=1304 and n=657
patients, respectively.
Main OutcomeMeasures The primary end point was 28-day all-cause mortality.
The secondary end points were all-cause mortality at 3, 6, and 12 months after be-
ginning treatment.
Results Baseline characteristics of the 2 study groups were similar. In the modified
intent-to-treat analysis (randomized patients who received at least 1 dose) there was
no significant difference in the primary end point of 28-day all-cause mortality with
28.1% (366/1304) in the eritoran group vs 26.9% (177/657) in the placebo group
(P=.59; hazard ratio, 1.05; 95%CI, 0.88-1.26; difference in mortality rate,1.1; 95%
CI, 5.3 to 3.1) or in the key secondary end point of 1-year all-cause mortality with
44.1% (290/657) in the eritoran group vs 43.3% (565/1304) in the placebo group,
Kaplan-Meier analysis of time to death by 1 year, P=.79 (hazard ratio, 0.98; 0.85-
1.13). No significant differences were observed in any of the prespecified subgroups.
Adverse events, including secondary infection rates, did not differ between study groups.
Conclusions and Relevance Among patients with severe sepsis, the use of eri-
toran, compared with placebo, did not result in reduced 28-day mortality.
Trial Registration clinicaltrials.gov Identifier: NCT00334828
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manifest by hypoperfusion of vital or-
gans, multiple organ dysfunction, and
death.1-3
The Surviving Sepsis Campaign re-
ported decreasedmortality based on im-
proved supportive care and evidence-
based guidelines for diagnosis and
timely intervention.4,5 However, mor-
tality remains at approximately 30%4
and hospital admissions for severe sep-
sis have increased.3,5,6 Thus, improve-
ments in care for severe sepsis remain
a priority.
Lipopolysaccharide (LPS) or endo-
toxin, themajor component of the outer
membrane of gram-negative bacteria, is
a potent stimulator of the inflamma-
tory response.7 LPS triggers inflamma-
tion in gram-negative sepsis. Exces-
sive amounts of gut-derived LPS
released during intestinal hypoperfu-
sion are implicated in sepsis caused by
gram-positive and fungal infections.8,9
LPS signaling is initiated by activa-
tion of the MD2:toll-like receptor 4
(TLR4) on myeloid cells.7,10 Eritoran
(E5564), a synthetic analog of lipid A
and a potent and specific antagonist of
LPS action, inhibits lipid A binding to
MD2 and terminates MD2/TLR4-
mediated signaling invitro, exvivo, and
invivo.11-13 In a phase 1 trial, eritoran
blocked cytokine responses and clini-
cal illness in healthy volunteers14 and
in a phase 2 trial, eritoran-treated pa-
tients at high risk of death had lower
mortality that was not statistically sig-
nificant (eritoran 37.5% vs placebo
56.3%).15
The current trial evaluated the safety
and efficacy of eritoran in reducingmor-
tality in patients with severe sepsis.
METHODS
The ACCESS (a controlled compari-
son of eritoran and placebo in patients
with severe sepsis) trial was designed
as a randomized, double-blind, placebo-
controlled, phase 3 clinical study. En-
rollment occurred from June 2006
through September 2010 in 197 sites
in North America, Europe, South
America, Africa, Asia, and Australia.
Predefined race and ethnicity informa-
tion categories (white; black; Asian,
non-Japanese; Japanese; other; His-
panic, non-Hispanic) were noted at
screening for planned subgroup analy-
ses of efficacy and safety. Racial cat-
egorieswere self-reported and these dif-
ferences were assessed to determine if
TLR4 polymorphisms from different
populations affected responsiveness to
eritoran therapy.
Patient Selection
Patients who were at least 18 years old
with early severe sepsis or septic shock
and high risk of deathwere screened for
participation. Severe sepsis was de-
fined as documented evidence of bac-
terial or fungal infection, at least 3 cri-
teria for systemic inflammatory response
syndrome (SIRS eAppendix, available at
http://www.jama.com), and at least 1
major organ dysfunction. Septic shock
wasdefinedashypotension requiringva-
sopressors (eAppendix). High risk of
deathwasdefined ashaving anAPACHE
II (AcutePhysiology andChronicHealth
Evaluation) score of at least 21 and not
greater than 37. The onset of the first
sepsis-related organ dysfunction had to
occur less than 12 hours before admin-
istration of the study drug. Key exclu-
sion criteria are listed in eAppendix.
Randomization
Eligible patients were assigned by cen-
tralized randomization using a com-
puterized set of random numbers in a
2:1 eritoran:placebo ratio. Patientswere
assessed daily until hospital discharge
or day 28 after randomization. Long-
term follow-up evaluations occurred at
3, 6, and 12 months.
Critical care and infectious disease
specialists at 3 clinical coordinating cen-
ters (United States, Belgium, and Ja-
pan) reviewed all screening data with
study sites before enrollment to con-
firm that patients met all inclusion but
no exclusion criteria. Approval from in-
stitutional review or ethics boards was
obtained for all sites, and written in-
formed consent was obtained from all
patients or proxies as required by lo-
cal authorities. A clinical evaluation
committee (eAppendix) performed
blinded evaluations of procedures
throughout the study. The clinical
evaluation committee determined the
type, site, and causative organism of
sepsis-defining infections.
Study Procedures
A total dose of 98.41 mg eritoran (free
acid) was administered. This amount is
equal to the highest total dose of eri-
toran tetrasodium (105mg) used in the
phase 2 severe sepsis study.15 Eritoran
wasadministered intravenouslyasa load-
ing dose of 26.24 mg (6.56 mg/h for 4
hours), followed by a second loading
doseof 13.12mg(6.56mg/h for 2hours)
12 hours later, and 9maintenance doses
of 6.56mg (3.28mg/h for 2hours) given
every 12hours thereafter.Matching pla-
cebo (vehicle) vials, with identical re-
constitution and infusion instructions to
the eritoran vials, were administered on
the same schedule.
Primary and Secondary Outcomes
Survival was ascertained at 28 days
after beginning treatment (the pri-
mary outcome measure) and at 3, 6,
and 12 months through interviews
with patients or surrogates. Serum
samples of inflammatory markers
were obtained at baseline, 30 minutes
before the second loading dose, and
on days 2 and 3. When not normally
distributed, log-transformation of
these data was performed for statisti-
cal analysis. Endotoxin activity assays
were performed at baseline in a subset
of patients by previously described
methods (eAppendix).9
Eritoran efficacy was evaluated in
prespecified patient subpopulations de-
fined as follows: baseline APACHE II
score groups (21-24, 24-26, 26-
31, and 31-37); gram-negative vs
gram-positive infections; infection sites
(lung, abdomen, genitourinary, skin/
soft tissue, primary and catheter-
related bacteremia, central nervous sys-
tem, and other); and baseline severity
of illness by Sequential Organ Failure
Assessment (SOFA) scores.
Safety Measures
Electrocardiograms, laboratory mea-
surements, and physical examina-
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tions were performed throughout the
active 28-day follow-up period or at
hospital discharge. Adverse eventswere
evaluated up to day 28 in all patients.
Infection-related adverse events were
closely monitored to assess the poten-
tial host response attenuation risk by
eritoran.15-17
Statistical Analysis
A modified intent-to-treat (MITT)
population, consisting of all random-
ized patients who received at least 1
dose of eritoran or placebo, was the pri-
mary population for analysis of eri-
toran efficacy. A per-protocol popula-
tion was determined by the clinical
evaluation committee’s adjudication of
study drug treatment compliance, eli-
gibility criteria, and lack of major pro-
tocol deviations. The safety popula-
tion consisted of all patients who
received at least 1 dose of study drug
and had at least 1 post-dose safety as-
sessment. An independent data moni-
toring committee conducted interim ef-
ficacy and safety analyses. Statistical
programming and analyses were per-
formed using SAS version 9.1.3, ser-
vice pack 4.
The primary efficacy end point was
evaluated by the difference in all-
cause 28-daymortality between the eri-
toran-treated and placebo-treated
groups using a 2 test. Kaplan-Meier es-
timates and log-rank statisticswere used
to assess survival time function
throughout the 28 days and 1 year from
treatment initiation. The outcome vari-
able for a preplanned logistic regres-
sion analysis was all-cause 28-daymor-
tality. Participants with unknown
mortality status (who were lost to fol-
low-up before day 28) were consid-
ered as dead. The logistic regression
analysis with treatment and APACHE
II score as fixed covariates was ap-
plied as a sensitivity analysis to sup-
port the primary analysis. The pre-
planned analysis of hazard ratio (HR)
was unadjusted. HRs (eritoran vs pla-
cebo) and CIs were based on a Cox re-
gression model with treatment group
as a covariate.
All-cause mortality of 40% was pre-
dicted for the placebo group based on
mortality rates in the phase 2 sepsis
study for patient subgroups with
APACHE II scores of 21 to 37.15 A
sample size of 2000 patients was
deemed sufficient to detect at least a
7.5% difference (estimated effect size
based on the phase 2 trial results) in the
28-day mortality rate between eri-
Figure 1. Populations of Patients With Severe Sepsis Who Were Screened and Randomized
to Receive Eritoran or Placebo
1304 Included in primary analysis
1305 Included in safety analysis
1304 Received eritoran as
randomized
1 Received eritoran without
randomization
657 Included in primary analysis
657 Included in safety analysis
1985 Eligible patients
2166 Provided informed consent and
underwent additional screening
3329 Patients underwent initial
screening for eligibility
1322 Randomized to receive eritoran
1304 Received eritoran as
randomized
18 Did not receive study drug
662 Randomized to receive placebo
657 Received placebo as
randomized
5 Did not receive study drug
181 Excluded
173 Did not meet eligibility criteria
1 Adverse event
1 Withdrew consent
6 Other
73 Met exclusion criteria
30 No documented evidence of infection
23 No qualifying organ failure
21 Other
26 Organ failure detected outside the
12-h time window
1163 Excluded (did not meet all inclusion criteria) a
1984 Randomized
1 Received eritoran
without randomization
aReasons for exclusion after initial screening are not available.
Table 1. Demographics of Patients With Severe Sepsis and High Risk of Death, MITT
Population
No. (%)
Eritoran (n = 1304) Placebo (n = 657)
Age, y
Mean (SD) 65.4 (15.0) 65.8 (15.1)
Median (range) 68 (18-99) 68 (18-96)
Men 766 (58.7) 379 (57.7)
Women 538 (41.3) 278 (42.3)
Race/ethnicity
Black 77 (5.9) 43 (6.5)
White 1032 (79.1) 512 (77.9)
Asian, non-Japanese 73 (5.6) 30 (4.6)
Japanese 83 (6.4) 53 (8.1)
Other 39 (3.0) 19 (2.9)
Abbreviations: MITT, modified intention to treat.
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toran and placebo,with 90%power and
an overall  level of .05 using a 2-sided
2 test. Four interim analyses were
planned and 1 additional safety in-
terim analysis was conducted by the
datamonitoring committee. The nomi-
nal  levels assigned for the first 3
planned interim safety analyses and the
additional interim safety analysis were
.0001, .0001, .0001, and .0001, respec-
tively. The final planned interim analy-
sis (considered as both efficacy and
safety) is assigned an  value of .001.
Adjusted for 5 interim analyses, the 
value assigned for the final analysis was
.0498 using the interpolated bound-
ary family.
RESULTS
Study Population
Written informed consent was
obtained from 2166 patients, 1984 of
whom were confirmed to be eligible
by the clinical coordinating centers.
These 1984 patients were randomized
(2:1) to receive eritoran (n=1322) or
placebo (n=662) (FIGURE 1). Enroll-
ment began in June 2006 and was
completed by Sepember 2010. One-
year followup on all patients was
completed by September 2011.
Among randomized patients, 18 in
the eritoran group and 5 in the pla-
cebo group did not receive treat-
ment. Therefore, the MITT popula-
t ion compr i sed 1961 pa t i en t s
(eritoran, n=1304; placebo, n=657).
One patient was treated with eritoran
without randomization and became
part of the safety population only
(1962 patients: eritoran, n=1305;
placebo, n=657). The vital status of
the entire MITT population was
determined at the 28-day follow-up
time point.
The 2 study groups were well bal-
ancedwith respect to demographic and
baseline disease characteristics
(TABLE 1, TABLE 2, and TABLE 3). The
median APACHE II score was 26 in
both groups. Septic shock was present
in approximately 80% of patients at en-
rollment, and 65% of patients had at
least 1 other organ dysfunction in ad-
dition to the initial organ dysfunction
Table 2. Baseline Disease Characteristics of Patients With Severe Sepsis and High Risk of
Death, MITT Population
No. (%)
Eritoran (n = 1304) Placebo (n = 657)
APACHE II score
Mean (SD)a 27.2 (4.5) 27.3 (4.5)
Median (range) 26.0 (18-46) 26.0 (21-49)
Patients by APACHE II categoryb
21 5 (0.4) 0
21-24 441 (33.8) 209 (31.8)
25-26 219 (16.8) 122 (18.6)
27-31 371 (28.5) 194 (29.5)
32-37 265 (20.3) 128 (19.5)
37 3 (0.2) 4 (0.6)
Patients by No. of SIRS criteriac
1 1 (0.1) 0
2 10 (0.8) 3 (0.5)
3 672 (51.5) 330 (50.2)
4 621 (47.6) 324 (49.3)
Patients by No. of organ dysfunctions
0 3 (0.3) 0
1 449 (34.4) 223 (33.9)
2 443 (34.0) 234 (35.6)
3 299 (22.9) 138 (21.0)
4 98 (7.5) 57 (8.7)
5 12 (0.9) 5 (0.8)
Organ dysfunctionsd
Acute lung injury/ARDS 296 (22.7) 164 (25.0)
Thrombocytopenia 221 (16.9) 102 (15.5)
Lactic acidosis 625 (47.9) 333 (50.7)
Shock 1070 (82.1) 533 (81.1)
Acute renal failure 472 (36.2) 226 (34.4)
SOFA scorese
Cardiovascular, No. of patients 1304 655
Mean (SD) 3.3 (1.21) 3.3 (1.20)
Median (range) 4.0 (0-4) 4.0 (0-4)
Respiratory, No. of patients 1272 643
Mean (SD) 2.7 (1.12) 2.7 (1.14)
Median (range) 3.0 (0-4) 3.0 (0-4)
Central nervous system, No. of patients 1273 640
Mean (SD) 1.6 (1.45) 1.6 (1.49)
Median (range) 1.0 (0-4) 1.0 (0-4)
Renal, No. of patients 1286 648
Mean (SD) 1.8 (1.47) 1.9 (1.45)
Median (range) 2.0 (0-4) 2.0 (0-4)
Coagulation, No. of patients 1030 538
Mean (SD) 0.6 (0.96) 0.6 (0.93)
Median (range) 0 (0-4) 0 (0-4)
Hepatic, No. of patients 1255 639
Mean (SD) 0.4 (0.80) 0.4 (0.76)
Median (range) 0 (0-4) 0 (0-4)
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation; ARDS, acute respiratory distress syndrome;
MITT, modified intention to treat; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure As-
sessment.
aAPACHE II scores range from 0 to 71. Higher scores indicate more severe disease.
bAPACHE II categories are based on the quartiles of the APACHE II score for all patients in the MITT population.
cSee eAppendix for SIRS criteria.
dNo. of patients with organ dysfunction may exceed No. in treatment group and percentages may total more than 100%
because some had more than 1 organ dysfunction.
eSOFA scores range from 0 (normal) to 4 (most abnormal).
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required for enrollment. Gram-
negative infections were documented
in 35% of patients in both groups and
gram-positive infections in 27%.Mixed
gram-negative/gram-positive infec-
tions occurred in 11% of patients. The
most common causative organisms
overall wereEscherichia coli (22%of pa-
tients), Staphylococcus aureus (12%),
and Streptococcus pneumoniae (11%).
The lung was the infection site in ap-
proximately half of patients in each
group. The overall incidence of blood-
stream infection was 40% in the pla-
cebo group and 37.5% in the eritoran-
treated group. The per-protocol
population, as adjudicated by the clini-
cal evaluation committee, consisted of
1760 patients (89.8% of the MITT
population).
Comparable supportive care was ad-
ministered during the 28-day study
(TABLE 4). More than 90% of patients
in both groups received some ele-
ments of early goal-directed sepsis
therapy and 67% of patients received
stress-dose systemic corticosteroids per
protocol. Approximately 15% of pa-
tients received drotrecogin alfa (acti-
vated) therapy. Appropriate antimicro-
bial therapy and timely infection control
was high in both treatment groups.
Efficacy Assessments
Treatment with eritoran did not sig-
nificantly alter the primary study end
point of 28-day mortality in the MITT
population; 28.1% (366/1304) of pa-
tients in the eritoran group vs 26.9%
(177/657) of patients in the placebo
group. The vital status was unknown
for 3 patients in each group (P=.60).
The difference in 28-day mortality be-
tween the eritoran and placebo groups
was1.1% (95% CI,5.3% to 3.1%).
The Kaplan-Meier survival analysis for
the 28-day period showed no differ-
ences between the groups (P=.58 by
log-rank test; [HR, 1.05; 95% CI, 0.88
to 1.26];FIGURE 2A). Similarly, Kaplan-
Meier analysis of the key secondary end
point, all-cause mortality at 1 year,
showed no differences in outcome
(P=.79 by log-rank test; [HR, 0.98; 95%
CI, 0.85 to 1.13]; Figure 2B).
Analysis of predefined subgroups, in-
cluding patients at different APACHE
II quartiles and baseline SOFA scores,
those with septic shock (as defined by
cardiovascular SOFA score2), those
with gram-negative and gram-positive
infections, and those with infection at
different sites (including bloodstream
infections or total confirmed infec-
tions), revealed no effect of eritoran on
mortality vs placebo (FIGURE 3). A
number of baseline variables were sig-
nificantly associated with outcome in-
cluding age, sex, race/ethnicity, num-
ber of organ dysfunctions, source of
infection types, and primary focus of in-
fection. A logistic regressionmodel ac-
counting for these variables failed to
demonstrate a significant effect of treat-
ment on outcome (P=.93).
Levels of interleukin (IL)-1	, IL-6,
IL-8, IL-10, IL-12, tumor necrosis fac-
tor (TNF)-, and procalcitoninwere el-
evated at baseline and decreased at sub-
sequent time points. The changes were
comparable for both groups (eTable 1).
Asanticipated, thecytokinedatawerenot
normally distributed.No significant dif-
ferenceswere observed between groups
by analyzing cytokine datawith orwith-
out log-transformation.
The overall 28-day mortality rate in
the subgroup of 209 patients for whom
baseline endotoxin levels were mea-
sured was 18.4% for patients treated
with eritoran and 29.4% for patients
who received placebo, a result not con-
sistent with the overall mortality rate
in the study. A total of 85 patients
(40.7%; 52 in the eritoran group and
33 in the placebo group) had elevated
baseline endotoxin activity assay (EAA)
(.6). In these patients, eritoran treat-
ment led to a 28-day mortality rate of
28.9% vs 27.3% in the placebo groups.
In the subgroup of patients with EAA
levels.6, the mortality rate was 12%
in the eritoran-treated group (n=83) vs
31.7% in the placebo group (n=41).
Safety Assessments
Eritoran was well tolerated with com-
parable numbers of treatment-
emergent adverse events (TEAEs) and
serious TEAEs between eritoran and
placebo groups (eTable 2). TEAEs of
special interest, including evidence of
atrial fibrillation, hepatic dysfunction,
Table 3. Baseline Infection Characteristics of Patients With Severe Sepsis and High Risk of
Death, MITT Population
No. (%)
Eritoran (n = 1304) Placebo (n = 657)
Patients by type of infection
Gram-negative 421 (32.3) 215 (32.7)
Gram-positive 349 (26.8) 182 (27.7)
Mixed gram-negative and gram-positive 136 (10.4) 76 (11.6)
Fungal 19 (1.5) 4 (0.6)
Viral 1 (0.1) 0
Mixed bacterial/fungal/other 34 (2.6) 15 (3.3)
Parasitic 0 0
Unknown 299 (22.9) 143 (21.8)
No evidence of infection 45 (3.5) 22 (2.3)
Infection sitesa
Lung 671 (51.5) 329 (50.1)
Abdomen 305 (23.4) 159 (24.2)
Genitourinary 268 (20.6) 149 (22.7)
Skin/soft tissue 122 (9.4) 55 (8.4)
Primary bloodstream 38 (2.9) 12 (1.8)
Catheter-related bacteremia 35 (2.7) 11 (1.7)
Central nervous system 31 (2.4) 14 (2.1)
Other 82 (6.3) 31 (4.7)
aNo. of patients with infection sites may exceed No. in treatment group and percentages may total more than 100%
because some had more than 1 infection site.
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renal dysfunction, hemorrhagic events,
or phlebitiswere similar in both groups.
TEAEs related to infection were com-
parable for both groups (placebo group,
47%; eritoran group, 46%).
COMMENT
In this phase 3 trial of patients with se-
vere sepsis, eritoran administration
failed to demonstrate a significant ef-
fect, compared with placebo adminis-
tration, on reducing all-cause 28-day
mortality, 1-year mortality, or on any
of the prespecified patient subgroups.
These findings are in contrast with sev-
eral preclinical studies and in phase 1
clinical trials in which eritoran termi-
nated lipopolysaccharide (LPS)-
associatedmolecular and clinical events
when administered in adequate
doses.11-15 Despite these promising early
results, no evidence of significant ben-
efit was observed with eritoran in this
large phase 3 trial.
Endotoxemia in the absence of an
identifiable gram-negative infection is
attributed to impaired mucosal bar-
rier functionwith increased permeabil-
ity of endotoxin and other pathogen-
associatedmolecular patterns from the
large reservoir of gram-negative bacte-
ria in the gut.8,9,18,19 Variable and inter-
mittent circulating LPS concentra-
tions are often found at some point
duringmost severe sepsis episodes and
the endotoxemia level correlates with
illness severity.8,9,18 Therefore, LPS has
long been considered an attractive tar-
get for potential antisepsis therapies.
Previous therapeutic strategies tar-
geted endotoxinwith antibodies against
the lipid A moiety of LPS,20,21 which
failed in clinical trials and were later
found to be weak binders and neutral-
izers of endotoxin in vitro.22 Other
therapies aimed at reducing LPS lev-
els, including bactericidal permeability-
increasing protein,23 phospholipid
emulsion,24 and polymixin B col-
umns25 also produced variable find-
ings with inconsistent clinical trial re-
sults. Our results with the highly active
LPS inhibitor eritoran in critically ill
septic patients call into question the role
of an endotoxin-blocking agent in halt-
ing the inflammatory progression and
organ dysfunction once sepsis is al-
ready underway.
There are multiple possible expla-
nations for why eritoran did not im-
prove treatment outcomes. First, the
original hypothesis was predicated on
the expectation that an LPS inhibitor
would limit damage attributable to el-
evated serum endotoxin levels in pa-
tients with established severe sepsis.
The study design was intended to cap-
ture severely ill patients at high risk of
endotoxemia in the early stages of pro-
gressive, sepsis-induced organ dysfunc-
tion. Based on previous observational
studies, we predicted that the major-
ity of patients enrolled would have el-
evated levels of circulating endo-
toxin.8,9 However, the study design did
not use detectable endotoxemia as a
precondition for enrollment and in the
Table 4. Summary of Background Care for Patients With Early Severe Sepsis and High Risk of
Death During the 28-Day Study, MITT Population
No. (%)
Eritoran
(n = 1304)
Placebo
(n = 657)
Followed the early goal-directed therapy protocol
Yes 1230 (94.3) 623 (94.8)
Fluid resuscitation 1206 (92.5) 605 (92.1)
Vasopressors 1123 (86.1) 567 (86.3)
Red cell transfusion 378 (29.0) 190 (28.9)
Central venous O2 monitoring 372 (28.5) 204 (31.1)
Dobutamine 242 (18.6) 141 (21.5)
No 74 (5.7) 34 (5.2)
Insulina
Yes 930 (71.3) 467 (71.1)
No 374 (28.7) 190 (28.9)
Drotrecogin alfa, activatedb
Yes 176 (13.5) 98 (14.9)
No 1128 (86.5) 559 (85.1)
Low tidal volume protocolsc
Yes 618 (47.4) 323 (49.2)
No 498 (38.2) 247 (37.6)
Not applicable 188 (14.4) 87 (13.2)
Baseline organ support
Renal dialysis 100 (7.7) 48 (7.3)
Vasopressor 1132 (86.8) 576 (87.7)
Mechanical ventilation 1024 (78.5) 535 (81.4)
Intensive care unit 1289 (98.8) 654 (99.5)
Appropriate antimicrobial therapy as adjudicated
by CEC
Yes 1199 (91.9) 612 (93.2)
No 59 (4.5) 23 (3.5)
Not applicable 46 (3.5) 22 (3.3)
Adequate source control of infection as adjudicated
by CEC
Yes 454 (34.8) 238 (36.2)
No 84 (6.4) 39 (5.9)
Not applicable 766 (58.7) 380 (57.8)
 1 Concomitant medicationd
Systemic steroidse 878 (67.3) 446 (67.9)
Antibiotics 1301 (99.8) 657 (100.0)
Abbreviations: CEC, clinical evaluation committee; MITT, modified intention to treat.
a Insulin was administered to provide intensive glycemic control during the study.
bDrotrecogin alfa activated (brand name, Xigris).
cLow-tidal volume protocols were followed while patients received support from mechanical ventilation (ie, 6 mL/kg).
dConcomitant medications were ongoing from baseline or started after the first dose of study medication.
ePatients receiving a mean dose of more than 0.5 mg/kg prednisone (to a maximum of 30 mg/d) or equivalent dose of
another agent in the 7 days prior to screening were excluded. Hydrocortisone at doses of at least 300 mg per day for
treatment of septic shock was acceptable.
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Figure 2. Kaplan-Meier Analysis of Time to Death by (A) Day 28 and (B) 1 Year in the MITT Population Who Received Eritoran or Placebo
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Patients who were alive past day 28 and at 1 year were censored at day 28 or at 1 year, respectively. Patients who did not die and were lost to follow-up within 28 days
or 1 year were censored at their last contact date. Plot areas tinted blue indicate data for days 0 through 28.
Figure 3.Mortality (28-Day) in Subpopulations in the Modified Intention to Treat Population Who Received Eritoran or Placebo
Favors Placebo Favors Eritoran
Difference in %
Mortality
(95% CI) P Value
Mortality, No. (%)
Placebo Eritoran
No. of Patients
Placebo Eritoran
APACHE II group
<21 0 (0.0)0 (0.0)5
>37 –16.7 (–90.7 to 57.4) .662 (50.0) 2 (66.7)4 3
>31- ≤37 2.4 (–7.7 to 12.6) .6449 (38.3) 95 (35.8)128 265
>26-≤31 –3.3 (–11.1 to 4.5) .4050 (25.8) 108 (29.1)194 371
>24-≤26 1.2 (–8.8 to 11.2) .8136 (29.5) 62 (28.4)122 219
40 (19.1) 99 (22.4)209
0
441≥21-≤24 –3.3 (–10.1 to 3.4) .34
5 (41.7)
97 (29.5)
10 (26.3)12
329
38 15.4 (–14.4 to 45.1)
Infection site
CNS –6.9 (–36.7 to 22.8) .654 (28.6) 11 (35.5)14 31
Skin/soft tissue –18.9 (–33.4 to –4.4) .019 (16.4) 43 (35.2)55 122
Abdomen 0.4 (–8.3 to 9.1) .9347 (29.6) 89 (29.2)159 305
Other –11.6 (–30.7 to 7.5) .247 (22.6) 28 (34.1)31 82
Catheter-related bacteremia –16.1 (–47.3 to 15.1) .312 (18.2) 12 (34.3)11 35
Genitourinary –7.1 (–15.3 to 1.1) .0925 (16.8) 64 (23.9)149 268
Primary bloodstream
Lung 200 (29.8)671 –0.3 (–6.4 to 5.7)
.31
.92
SOFA scores-cardiovascular
0-1 –7.2 (–17.7 to 3.3) .1820 (20.4) 56 (27.6)98 203
156 (28.0) 310 (28.2)557 11012-4 –0.1 (–4.7 to 4.4) .95
SOFA scores-respiratory
0-1 –5.2 (–16.0 to 5.6) .3520 (21.3) 46 (26.4)94 174
154 (28.1) 307 (28.0)549 10982-4 0.1 (–4.5 to 4.7) .97
SOFA scores-CNS
0-1 –0.8 (–6.3 to 4.7) .7888 (24.3) 172 (25.1)362 685
83 (29.9) 177 (30.1)278 5882-4 –0.2 (–6.8 to 6.3) .94
SOFA scores-renal
0-1 0.9 (–4.7 to 6.6) .7462 (21.5) 127 (20.6)288 617
111 (30.8) 233 (34.8)360 6692-4 –4.0 (–10.0 to 2.0) .20
SOFA scores-coagulation
0-1 –1.1 (–6.0 to 3.9) .67105 (23.7) 208 (24.8)443 839
35 (36.8) 70 (36.6)95 1912-4 0.2 (–11.7 to 12.1) .97
SOFA scores-hepatic
0-1 –1.6 (–6.2 to 2.9) .49144 (25.9) 298 (27.5)556 1083
28 (33.7) 44 (25.6)83 1722-4 8.2 (–3.6 to 19.9) .18
Infection type
Gram positive –9.1 (–17.4 to –0.8) .0345 (24.7) 118 (33.8)182 349
48 (22.3) 92 (21.9)215 421Gram negative 0.5 (–6.3 to 7.3) .89
–100 –50 500 100
Difference, % (95% CI)
CNS indicates central nervous system.
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substudy of 209 patients who had base-
line endotoxin levelsmeasured byEAA,
a surprisingly low percentage (41%)
had high endotoxin levels (.6).9
Second, the observed mortality rate
for patientswho receivedplacebo (27%)
was lower than the anticipatedmortal-
ity rate (40%) used in the original de-
sign. The low placebo event rate, which
may indicate less severe disease in our
patient population, would predict a
lower response probability to eri-
toran. Consequently, this study might
have beenunderpowered to detect a dif-
ference in outcome in this lower than
expected mortality risk population.16
Third, improvements in patient care
may also have contributed to a lower
placebo event rate in this study than in
previous trials. The APACHE 2 score
as a predictor of intensive care unitmor-
tality was validatedmore than 20 years
ago and now consistently overesti-
mates the mortality rate in sepsis pa-
tients.26 Themajority of patients had ag-
gressive fluid resuscitation as part of
early goal-directed therapy and were
treated in accordance with Surviving
Sepsis Campaign guidelines.4 In addi-
tion, approximately 70% of patients re-
ceived appropriate antimicrobial
therapy within 4 hours of diagnosis,
which probably improved survival. In
patients with meningococcal sepsis,
early administration of appropriate an-
tibiotic therapy correlated with rapid
clearance of endotoxin.27 A possible re-
lated factor was the delayed timing of
eritoran administration, (ie, started a
median of 9.15 hours after the onset of
sepsis-inducedorgandysfunction). This
may not have been early enough to pro-
vide benefit for some endotoxemic pa-
tients with sepsis.
Fourth, in subgroup analyses, pa-
tients with gram-positive bacterial in-
fections and those with skin and soft
tissue infections appeared to do signifi-
cantly worse in the eritoran-treated
group than the placebo group. In the
phase 2 trial, the subgroup of patients
with gram-positive bacterial infec-
tions seemed to respond better to eri-
toran than thosewith gram-negative in-
fections.15 The reasons for these
differential outcomes between studies
in gram-positive bacterial sepsis are un-
clear, but are most likely attributable
to chance when analyzing differences
between small subgroups. Future trials
with this or other MD2-TLR4 inhibi-
tors should proceed with caution if pa-
tients with gram-positive infections are
included in the study population.
Many drugs commonly used inman-
agement of critically ill patients with
sepsis can alter the host response to
TLR4 signaling directly or indirectly,
potentially limiting the benefits of this
specific MD2:TLR4 inhibitor. Gluco-
corticoids, statins, catecholamines,mac-
rolides, anesthetics, proton pump in-
hibitors, and other agents can modify
the host inflammatory response and al-
ter responsiveness to LPS inhibitors.28
Although LPS acts via TLR4 to acti-
vate NF-kappa-B and inflammatory
gene transcription, other host-derived
andmicrobial ligands are recognized by
a number of pattern recognition recep-
tors and can activate NF-kappa-B–
dependent gene transcription indepen-
dent of TLR4 signaling.7,29-31 Other
common intermediary steps in the in-
flammatory cascade may be better tar-
gets for intervention.
In summary, in this phase 3 trial eri-
toran did not significantly improve out-
come for patientswith severe sepsis and
septic shock. Eritoran joins a long list
of other experimental sepsis treat-
ments that do not improve outcomes
in clinical trials in these critically ill pa-
tients.
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